__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Beovu is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to diabetic macular oedema (DMO).1,2
AMD, age-related macular degeneration.
References
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics Great Britain.
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics Northern Ireland.